# Study of E7389 Liposomal Formulation in Participants With Solid Tumor

> **NCT03207672** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** E7389-LF

## Key facts

- **NCT ID:** NCT03207672
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-18
- **Primary completion:** 2018-07-19
- **Final completion:** 2027-03-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207672, "Study of E7389 Liposomal Formulation in Participants With Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03207672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*